DHR
DANAHER CORP /DE/
NYSE · Healthcare · Medical - Diagnostics & Research · US
$236.94
+1.23%Next report
Analyst consensus
- Next report date
- Jan 27, 2027
- EPS estimate
- $2.48
- Revenue estimate
- $7.5B
Latest reported
- Last report date
- Oct 21, 2026
- EPS actual
- $2.11
- EPS estimate
- $1.92
- Revenue actual
- $6.6B
- Revenue estimate
- $6.5B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +6.0%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $258
- PT range
- $240 – $270
- Analysts
- 10
10 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 21, 2026 | $1.92 | $2.11 | Beat 9.78% | $6.6B |
| Jul 21, 2026 | $1.85 | $1.94 | Beat 4.75% | $6.3B |
| Apr 21, 2026 | $1.94 | $2.06 | Beat 6.19% | $6.0B |
| Jan 28, 2026 | $2.16 | $2.23 | Beat 3.24% | $6.8B |
| Oct 21, 2025 | $1.72 | $1.89 | Beat 9.88% | $6.1B |
| Jul 22, 2025 | $1.64 | $1.80 | Beat 9.76% | $5.9B |
| Apr 22, 2025 | $1.63 | $1.88 | Beat 15.34% | $5.7B |
| Jan 29, 2025 | $2.14 | $2.14 | In line | $6.5B |
| Oct 22, 2024 | $1.57 | $1.71 | Beat 8.92% | $5.8B |
| Jul 23, 2024 | $1.57 | $1.72 | Beat 9.55% | $5.7B |
| Jan 30, 2024 | $1.90 | $2.09 | Beat 10.00% | $2.7B |
| Jul 25, 2023 | $2.00 | $2.05 | Beat 2.50% | $7.2B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Jan 27, 2027